Oncology
Latest news
915 articles · 20 / page
Serplulimab Plus Chemotherapy Sustains Survival Advantage in ES-SCLC: Insights from the ASTRUM-005 Trial and Novel Biomarker Profiles
Updated ASTRUM-005 results confirm serplulimab’s significant survival benefit in extensive-stage small-cell lung cancer (15.8 vs. 11.1 months). Exploratory analyses identify a 15-protein signature and RB1/Notch mutations as potential predic
A Decadel Leap: TCX Regimen Outperforms Standard TAC in 10-Year Survival for High-Risk HER2-Negative Breast Cancer
A 10-year randomized trial reveals that replacing anthracyclines with capecitabine (TCX) significantly improves overall survival and reduces toxicity compared to the standard TAC regimen in high-risk, HER2-negative breast cancer patients.
Breaking Resistance: SBRT Plus Cadonilimab Shows Promising Efficacy in Heavily Pretreated Refractory Solid Tumors
A Phase 1b study demonstrates that combining SBRT with the bispecific antibody cadonilimab (PD-1/CTLA-4) is safe and effective for refractory solid tumors, yielding a 23.8% response rate and 7.2-month median PFS in patients who failed multi
Personalizing Neoadjuvant Intensity: 5-Year CinClare Data Validate UGT1A1-Guided Irinotecan for Rectal Cancer
The 5-year update of the CinClare trial demonstrates that adding irinotecan to neoadjuvant chemoradiotherapy, guided by UGT1A1 genotype, significantly improves long-term survival and disease-free outcomes in patients with locally advanced r
Bevacizumab and Fractionated Stereotactic Radiotherapy: A Synergistic Breakthrough for Extensive Brain Metastases in NSCLC
The GASTO-1053 phase II study demonstrates that combining bevacizumab with fractionated stereotactic radiotherapy significantly improves intracranial progression-free survival (18.3 months) and quality of life for NSCLC patients with extens
Global Gastrointestinal Cancer Burden to Nearly Double by 2050: A Critical Call for Targeted Prevention and Resource Allocation
By 2050, global gastrointestinal cancer incidence is projected to surge by 85%, reaching 9.06 million cases annually. While gastric cancer rates are declining, colorectal and pancreatic cancers are rising sharply, particularly in low and me
Adjuvant Camrelizumab plus Capecitabine Extends Recurrence-Free Survival in Resected Intrahepatic Cholangiocarcinoma: Results from the Phase 2 ACC Trial
The Phase 2 ACC trial demonstrates that adjuvant camrelizumab combined with capecitabine achieves a median recurrence-free survival of 24.29 months for patients with resected intrahepatic cholangiocarcinoma, offering a promising and managea
Tinengotinib Offers a Potential Breakthrough for FGFR-Inhibitor Resistant Cholangiocarcinoma
A Phase 2 trial demonstrates that tinengotinib, a multi-kinase inhibitor, shows significant clinical activity in patients with advanced cholangiocarcinoma who have progressed on prior FGFR inhibitors, particularly those with acquired resist
Atezolizumab and BCG Combination Fails to Improve Event-Free Survival in High-Risk NMIBC: Results from the ALBAN Phase III Trial
The Phase III ALBAN trial found that adding atezolizumab to BCG therapy did not improve event-free survival in BCG-naive high-risk non-muscle-invasive bladder cancer, highlighting the complexity of immune checkpoint inhibitor synergy in thi
Cancer Statistics in the United States, 2026: Trends, Disparities, and Future Challenges
In 2026, approximately 2.1 million new cancer cases and 626,140 deaths are projected in the U.S. Advances in prevention, early detection, and treatment have increased survival rates and averted millions of deaths, yet disparities and rising
Retifanlimab Plus Chemotherapy Significantly Extends Overall Survival in First-Line Metastatic NSCLC: Insights from the POD1UM-304 Phase 3 Trial
Executive Highlights The POD1UM-304 phase 3 trial marks a significant milestone in the management of...
Radiotherapy-Free Pembrolizumab and Chemotherapy Challenge the Standard of Care in PD-L1 High Locally Advanced NSCLC
The Phase 2 Evolution trial suggests that for unresectable, locally advanced NSCLC with PD-L1 TPS ≥50%, a radiotherapy-free regimen of pembrolizumab plus chemotherapy is feasible, yielding a 67% 2-year progression-free survival rate and a m
Beyond Conventional Immunotherapy: Zhenqi Fuzheng Granule Synergizes with PD-1 Blockade by Remodeling Gut-Immune Metabolism in Colorectal Cancer
Researchers have discovered that Zhenqi Fuzheng Granule enhances PD-1 antibody efficacy in colorectal cancer by modulating the gut microbiota-SCFA-GPR109A axis, effectively suppressing tumor glycolysis and reversing immune exhaustion within
Postoperative Lymph ctDNA Outperforms Plasma in Predicting Early Recurrence of HPV-Independent Head and Neck Cancer
Research identifies postoperative lymphatic exudate as a superior source of ctDNA for detecting molecular residual disease in HPV-independent head and neck cancer. This proximal liquid biopsy significantly outperforms plasma in predicting l
Adding Ianalumab to Ibrutinib Induces Deep Remissions and Enables Therapy Discontinuation in Chronic Lymphocytic Leukemia
A Phase Ib study reveals that adding the anti-BAFF-R antibody ianalumab to ibrutinib therapy achieves high rates of undetectable measurable residual disease (uMRD), allowing over 40% of CLL patients to successfully discontinue long-term tre
Machine Learning Accurately Predicts Distant Recurrence and Ribociclib Treatment Benefit in HR+/HER2- Early Breast Cancer
Researchers have developed a machine learning model using real-world and clinical trial data to predict distant recurrence risk and ribociclib’s therapeutic effect in HR+/HER2- early breast cancer, offering a potential tool for personalized
Does PD-L1 Inhibition Enhance CAR T-Cell Therapy? Long-Term Insights from the ZUMA-6 Trial in Refractory DLBCL
The ZUMA-6 trial investigated combining axicabtagene ciloleucel with atezolizumab for refractory DLBCL. While the combination was safe with a 54% complete response rate, efficacy and CAR T-cell expansion were comparable to monotherapy, high
Dual Inhibition of VEGF and EGFR: A New Precision Paradigm for Krebs Cycle-Mutated Solid Tumors
The Phase II BRISK trial demonstrates that the combination of bevacizumab and erlotinib provides significant clinical activity in patients with solid tumors harboring Krebs cycle gene mutations, particularly in FH-deficient renal cell carci
HER2-Positivity in Advanced Biliary Tract Cancer: A Dual Role as a Negative Prognostic Factor and a Potent Therapeutic Vulnerability
A multi-institutional analysis reveals that HER2-positivity in advanced biliary tract cancer signals a poorer prognosis but offers a significant survival benefit when targeted with anti-HER2 therapies, advocating for routine screening and s
Advances in Head and Neck Cancer: How Pre-Surgical Immunotherapy is Transforming Patient Outcomes
A Phase II clinical trial demonstrates that combining tislelizumab with neoadjuvant chemotherapy significantly improves pathological response rates and organ preservation in patients with locally advanced head and neck squamous cell carcino
Browse by specialty
Open language-specific specialty feeds and department pages.